1051 related articles for article (PubMed ID: 17332177)
1. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
3. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
4. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
6. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
[TBL] [Abstract][Full Text] [Related]
7. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
12. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
[TBL] [Abstract][Full Text] [Related]
13. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
[TBL] [Abstract][Full Text] [Related]
20. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
